Steve Thorne

Company: Kalivir Immunotheraputics

Job title: Chief Scientific Officer

Seminars:

Workshop B – Regulatory Guidance for Clinical Stage Oncolytic Virotherapy 1:00 pm

As T-Vec exists as the only approved oncolytic virotherapy for patients, the regulatory environment and the clinical production of OV’s remain complex as ever. Led by biopharma leaders, this session will set out to deconvolute the regulatory landscape of OV clinical development, taking vital learnings from the Cell and Gene Therapy environment. Topics to Cover:…Read more

day: Pre-Conference Workshop Day

VET3-TGI, An Oncolytic Vaccinia Targeting TGF-Beta 5:15 pm

TGF-beta inhibition is a potentially powerful approach to cancer therapy Oncolytic viral expression of a TGF-beta inhibitor overcomes many of the limitations of existing therapies Development of a multi-mechanistic oncolytic virus incorporating a TGF-beta inhibitor results in a potent pre-clinical cancer therapyRead more

day: Day One